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JPET#65573
JPET#65573 5 increased production of ET-1 occurs in the synovial fluid compared to plasma in patients with inflammatory arthritides (Miyasaka et al., 1992) , a fact confirmed more recently in rheumatoid arthritic patients (Haq et al., 1999) and arthritic joints (Gutierrez et al., 1996) .
ET-1 release has long been known to lead to neutrophil migration in rabbits (Elferink and de Koster, 1994) and cause neutrophil driven ischaemia in hearts (Andrasi et al., 2002 ).
An efficacy with antagonists directed at the ET-1 receptors at inhibiting inflammation has also been demonstrated in models of asthma with FR139317 inhibiting airway hyperresponsiveness (D'Agostino et al., 1999) , lung eosinophilia (Fujitani et al., 1997) and paw oedema (Sampaio et al., 1995) .
To date no studies have investigated the role of ET-1 anatgonists in gouty arthritis, a neutrophil driven pathology in which MSU crystals cause the influx of neutrophils into the joint articular space.
In this study we have investigated the effects of the ETA, FR139317 (Sogabe et al., 1993 , Filep et al., 1995 , ETB, BQ-788 (Karaki et al., 1994 , Hayasaki et al., 1996 and ET(A&B), PD145065 (McMurdo et al., 1993 , Battistini et al. 1994 antagonists on neutrophil migration in a murine model of experimental gouty peritonitis when administered either prophylactically or therapeutically. We have also evaluated their effect on adhesion molecule expression and release of pro-inflammatory chemokines and cytokines from cultured macrophages (MØ) and endothelial cells. JPET#65573 crystals (a concentration chosen from previous experiments) (Getting et al., 1999) and cell-free supernatants collected 2 h later. KC levels were measured by ELISA as described above.
PMN CD11b up-regulation: a whole blood protocol was used to quantify CD11b expression in basal conditions and after cell stimulation (Tailor et al., 1997) . Briefly, 1 ml of mouse blood was incubated with the different antagonists (1000 nM) for 15 min at 37°C in a shaker water bath prior to addition of 0.1 µM platelet-activating factor (PAF) and a further 15 min incubation. Control tubes were incubated without PAF. At the end, blood aliquots (200 µl) were incubated with rat IgG (10 µg/ml) or rat anti-mouse CD11b (clone 5C6; Serotec, Oxford, UK). After 1h at 4°C, FITC-conjugated rabbit anti-mouse IgG was added for a further 45 min, and FACS analysis performed using a FACScan II analyser (Becton Dickinson, Mountain View, CA) with air-cooled 100 mV argon ion laser tuned to 448 nm and a Consort 32 computer running Lysis II software. CD11b expression was measured in the FL1 (green) channel and quantified as computed units (channel numbers) and expressed as median fluorescence intensity (MFI).

RESULTS
Effect of ET-1 antagonists on PMN accumulation and KC levels in a model of MSU crystal peritonitis.
As shown in Table 1 , the in vivo administration of FR139317, BQ-788 and PD145065 did not alter circulating peripheral blood leukocyte counts or plasma levels of the CXC chemokine KC as measured at 2 h following collection of blood by cardiac puncture.
We then evaluated the effect of selective and mixed antagonists on PMN migration and as a marker of inflammation, the CXC chemokine KC in cell-free lavage fluids. The selective ETA antagonist FR139317 caused a dose dependent attenuation of PMN migration into the peritoneal cavity. The highest dose tested (1000 pmol) here caused a 32 % reduction, 300 pmol caused a more modest 15% reduction, whilst the lowest doss was essentially inactive ( Figure 1A ). At the anti-migratory dose of 1000 pmol, FR139317 caused a significant attenuation of KC release into the peritoneal cavity, with a 28% reduction being observed. Surprisingly the lower dose of 300 pmol caused a 40% reduction in KC release ( Figure 1B ). The selective ETB antagonist BQ-788 showed a similar degree of inhibition at 300 and 1000 pmol with a 25% and 35% reduction being observed respectively (Figure 2A ). However, this antagonist was unable to inhibit the release of the CXC chemokine KC into peritoneal cavity ( Figure 2B ). To ascertain if inhibition of both receptors led to an enhanced anti-inflammatory effect, the mixed ET(A&B) antagonist PD145065 was evaluated. At 1000 pmol we were able to inhibit PMN migration by 54% whilst lower doses were not effective ( Figure 3A) . KC release into the peritoneal cavity was inhibited at 1000 pmol by 31% ( Figure 3B ). In naïve mice JPET#65573 the number of PMN and level of KC was below the detection limits of these assays (data not shown).
Therapeutic administration of the selective ET-1 antagonists on PMN accumulation in experimental gout.
In these experiments the therapeutic potential of the antagonists was evaluated at the dose of 1000 pmol per mouse since this was found to be the most active when given prophylactic. The selective ETA antagonist FR139317 caused a non-significant 25% reduction in the neutrophil migration into the peritoneal cavity when given 2 h after the initiation of the inflammatory response ( Figure 4A ) and this inhibition was associated with a 32% reduction in the CXC chemokine KC ( Figure 4B ) and 23% reduction in IL-1β release ( Figure 4C ). A different scenario was observed for the selective ETB antagonist BQ-788 this failed to significantly attenuate the neutrophil migration ( Fig.   4A ), KC or IL-1β levels ( Figure 4B and C). To ascertain if inhibition of both receptors led to an enhanced therapeutic anti-inflammatory effect the mixed ET(A&B) antagonist PD145065 was evaluated. PMN migration was inhibited by 51% ( Figure 4A ), whilst KC ( Figure 4B ) and IL-1β (Figure. 4C) were both inhibited a significant 32%.
Effect of anti-migratory dose of endothelin antagonists over a time course
We next decided to see if the antagonists were able to modulate the inflammatory response elicited by MSU crystals over a time course. Mice were treated with 1000 pmol of PD145065, FR139317 or BQ-788 and their effects on PMN migration and release of KC were investigated at different time points. MSU crystal injection caused a peak release of the chemokine at 2 h (3272 ± 190 pg/ml) it then fell dramatically to 882 ± 125 pg/ml at 6 h and back to a near basal level between 24 and 48 h. The maximal detection of PMN migration was observed 6 h following MSU crystal injection and remained high up to 24 h. Investigation of the effect of the mixed antagonist PD145065 showed a significant reduction of 38% at 2h reducing PMN migration from 1.3 ± 0.3 to 0.8 ± 0.1 x10 6 /mouse (*P<0.05 vs. PBS, n=4) and a 33% reduction in the release of the CXC chemokine KC reducing it from 3272 ± 190 to 2192 ± 75 pg/ml (*P<0.05 vs. PBS, n=4).
At the later time point of 24 h an anti-migratory effect was observed, although no effect was seen at 48 h. With respect to the chemokine an inhibitory effect was seen at 6 h although at later time-points no effect was observed. We next evaluated the ETA antagonist FR139317 that was inactive at 2, 24 and 48 h post MSU crystal-injection and caused a modest but significant inhibition at 6 h. A strange observation was noted with respect to KC release with a significant reduction of 23% from 3272 ± 190 to 2515 ± 176 pg /ml at 2 h (P<0.05 vs. PBS, n=4) and 28% at 6 h, whilst no effect was observed at any other time-point. Finally the ETB antagonist BQ-788 was evaluated and found to be antimigratory at 6 and 24 h post MSU crystal stimulation although no effect was observed on KC release (Table 2) . to inhibit IL-1β release, whilst BQ-788 caused a non-significant inhibition of 36% at 300 nM and a significant 60% inhibition at 1000 nM respectively. PD145065 caused a 28% reduction at 300 nM similar to that observed for BQ-788, whilst at 1000 nM there was a significant inhibition of 52% ( Figure 5A ). A different scenario was observed with respect to the effect of the antagonists on ET-1 release. FR139317 and BQ-788 were inactive and failed to inhibit ET-1 release. However, antagonism of both receptors using PD145065 caused a near complete abrogation of ET-1 release at 1000 nM with an approximate 90% reduction being observed ( Figure 5B ).
In vitro
Effect of ET-1 antagonists on KC release in vitro from cultured peritoneal MØ.
The effect of ET-1 anatgonists on release of the CXC chemokine KC in vitro was evaluated as a marker of MØ activation. The ETA antagonist FR139317 at 1000 nM caused a 57% reduction in KC levels from 456 ± 103 pg/ml to 198 ± 14 pg/ml (*P<0.05, n=4). PD145065 caused a 45% reduction whilst BQ-788 was inactive ( Figure 6A ).
Effect of ET-1 antagonists on PAF induced CD11b expression on murine PMN.
The effect of ET-1 antagonists on PAF induced CD11b expression in vitro was evaluated as a marker of PMN activation. PAF (0.1 µM) caused a significant increase in CD11b expression of 210 ± 16 MFI units compared to PBS 104 ± 20 (*P<0.05, n=3). Treatment of whole blood with FR139317 and PD145065 at 1000 nM caused a 28% and 31% reduction respectively in CD11b expression (*P<0.05 vs. PBS, n=3) whilst no effect was observed with BQ-788 ( Figure 6B ).
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DISCUSSION
In this study we report the novel discoveries that ET-1 antagonists are anti-inflammatory in a model of experimental MSU peritonitis. They exert their effects in part by suppressing the release of chemotactic agents and reducing adhesion molecule expression, ultimately leading to inhibition of neutrophil accumulation. This study has been prompted by the observation that ET-1 led to the migration of rabbit neutrophils (Elferink and de Koster, 1994) . However, we now report here for the first time that ET-1
antagonists are efficacious in a murine model of gouty peritonitis. These data suggest that antagonism of ET receptors could be of benefit in neutrophil driven pathologies.
MSU crystals injected into the peritoneal cavity have been shown to produce an intense and long-lasting accumulation of PMN into the mouse peritoneal cavity, recently characterized in terms of role of resident cells and requirements for adhesion molecules (Getting et al., 1997) . Prior to the accumulation of PMN there is a release of chemotactic cytokines and chemokines during this inflammatory reaction (Getting et al., 1999) . In this study we decided to monitor the CXC chemokine KC and the pro-inflammatory cytokine IL-1β, since these have been shown to be produced in other models of experimental (Terkeltaub et al., 1998 , Matsukawa et al., 1998 and human (Hachicha et al., 1995 , di Giovine et al., 1991 We then investigated if these antagonists possessed any therapeutic potential, so they were administered after the onset of inflammation. Antagonists were administered 2 h after MSU crystal injection, the time-point chosen due to the fact that this is where the peak release of the CXC chemokine KC was observed (Getting et al., 1999) . Both FR139317 and BQ-788 caused a modest inhibition although this was not significant and little effect on the levels of detectable KC and IL-1β were observed. However, a significant inhibition was observed for the mixed antagonist PD145065 and its antimigratory effect appeared to be due to inhibition of KC and IL-1β. These findings are not surprising given the fact that this antagonist when dosed prophylactically inhibited the release of this chemokine. Therefore antagonism of both receptors appears to be required once the inflammatory response has been initiated for an anti-migratory effect to occur. The requirement of switching off both receptors for an enhanced antiinflammatory profile is not altogether surprising given the fact that ETA receptors are expressed on neutrophils and FR139317 can inhibit ET-1 induced up regulation of CD11b/CD18 expression, whilst BQ-788 had no effect. However, BQ-788 but not FR139317 can inhibit ICAM-1 expression on endothelial cells (Zouki et al., 1999) .
Given the anti-migratory effects of these antagonists their effect over a time course was evaluated as to allow determination at which time point they exerted their effects. MSU crystal injection caused a peak of release of the chemokine KC at 2 h and this was followed by a maximal accumulation of PMN at 6 h and is in agreement with previous studies (Getting et al., 1997) . At the 2 h time-point only PD145065 inhibited PMN migration whilst at 6 h all antagonists were anti-migratory. At 24 h only the mixed and something that we were unable to do this could be due to the different strain of mice used (C57 compared to Swiss albino).
Finally given the fact that ET-1 receptors can be activated by PAF (Yoshizumi et al., 1990) , we investigated the effect of the antagonists on PAF induced up regulation of CD11b expression on murine PMN. FR139317 and PD145065 inhibited CD11b expression whilst BQ-788 was inactive. Given that ET-1 has been shown to down regulate the expression of L-selectin and increases CD11b expression (Zouki et al., 1999) , a scenario that will lead to an increase in leukocyte migration. Our findings showing an effect of the ETA and ET(A&B) antagonist but no effect with an ETB antagonist are in agreement with this study.
In conclusion the ET antagonists display novel anti-migratory effects in a murine model of MSU crystal-induced inflammation. Different profiles were observed for each antagonist and their effect was altered depending on whether given prophylactically or therapeutically. The data would also suggest that inhibition of both receptors lead to an enhanced anti-inflammatory effect and is partially due to the fact that the antagonists would target the release and action of cytokines and chemokines, and adhesion molecule expression either on the surface of the emigrating PMN or on the endothelium. These findings suggest that ET antagonists could be beneficial in treating certain inflammatory conditions. In the future further studies could be utilised in the rabbit as both CXCR1
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